10x Genomics, Inc. (TXG): who owns it and who trades it
As of Nov 16, 2026, TXG insiders reported 51 open-market sales worth $18.8M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Serge Saxonov (CEO), with $8.8M. 8 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling 10x Genomics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TXG
393 funds and institutions reported TXG shares worth $5.1B at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $676M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 17.63M | – | $676M | -1% |
| BlackRock, Inc. | 10.80M | – | $414M | +7% |
| ARK Investment Management LLC | 10.00M | – | $384M | -15% |
| Vanguard Portfolio Management LLC | 6.98M | – | $268M | +1% |
| Quantinno Capital Management LP | 5.47M | – | $210M | +1% |
| Vanguard Capital Management LLC | 5.08M | – | $195M | -4% |
| California State Teachers Retirement System | 4.68M | – | $122M | +3700% |
| T. Rowe Price Associates | 4.54M | – | $174M | +2681% |
| Sumitomo Mitsui Trust Group, Inc. | 4.19M | – | $161M | -18% |
| Amova Asset Management Americas, Inc. | 4.19M | – | $161M | -18% |
| Morgan Stanley | 3.35M | – | $129M | +26% |
| Goldman Sachs Group Inc | 3.15M | – | $121M | -21% |
| Geode Capital Management, LLC | 3.08M | – | $118M | +6% |
| State Street Corp | 2.80M | – | $107M | +8% |
| Citadel Advisors LLC | 2.78M | – | $107M | +274% |
| Dimensional Fund Advisors LP | 2.23M | – | $85.3M | +9% |
| AQR Capital Management LLC | 2.03M | – | $74.7M | -20% |
| Jacobs Levy Equity Management, Inc | 2.02M | – | $77.4M | -12% |
| Point72 Asset Management, L.P. | 1.85M | – | $71M | – |
| Capital World Investors | 1.49M | – | $57.2M | +3% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TXG insiders reported $0 of open-market purchases and $18.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Serge Saxonov | CEO | Sale | 31,000 | $62.90 | $1.9M | Form 4 |
| Sep 22, 2026 | Shehnaaz Suliman | Director | Sale | 1,325 | $80.82 | $107K | Form 4 |
| Sep 22, 2026 | Shehnaaz Suliman | Director | Sale | 2,270 | $81.67 | $185K | Form 4 |
| Sep 22, 2026 | Shehnaaz Suliman | Director | Sale | 292 | $78.20 | $22.8K | Form 4 |
| Sep 22, 2026 | Shehnaaz Suliman | Director | Sale | 614 | $79.51 | $48.8K | Form 4 |
| Sep 22, 2026 | Shehnaaz Suliman | Director | Sale | 1,222 | $82.28 | $101K | Form 4 |
| Sep 22, 2026 | Serge Saxonov | CEO | Sale | 1,000 | $78.23 | $78.2K | Form 4 |
| Sep 22, 2026 | Serge Saxonov | CEO | Sale | 9,900 | $81.83 | $810K | Form 4 |
| Sep 22, 2026 | Serge Saxonov | CEO | Sale | 9,300 | $80.90 | $752K | Form 4 |
| Sep 22, 2026 | Serge Saxonov | CEO | Sale | 2,000 | $79.62 | $159K | Form 4 |
| Sep 22, 2026 | Serge Saxonov | CEO | Sale | 2,800 | $82.37 | $231K | Form 4 |
| Sep 9, 2026 | Adam Taich | CFO | Sale | 1,206 | $63.68 | $76.8K | Form 4 |
| Sep 9, 2026 | Adam Taich | CFO | Sale | 13,754 | $65.26 | $898K | Form 4 |
| Sep 9, 2026 | Adam Taich | CFO | Sale | 31,428 | $64.31 | $2M | Form 4 |
| Sep 3, 2026 | John R Stuelpnagel | Director | Sale | 6,814 | $62.11 | $423K | Form 4 |
| Sep 3, 2026 | John R Stuelpnagel | Director | Sale | 7,012 | $60.66 | $425K | Form 4 |
| Sep 3, 2026 | John R Stuelpnagel | Director | Sale | 6,174 | $62.61 | $387K | Form 4 |
| Aug 26, 2026 | Serge Saxonov | CEO | Sale | 3,500 | $63.02 | $221K | Form 4 |
| Aug 26, 2026 | Serge Saxonov | CEO | Sale | 6,494 | $63.98 | $415K | Form 4 |
| Aug 26, 2026 | Serge Saxonov | CEO | Sale | 492 | $64.75 | $31.9K | Form 4 |
| Aug 24, 2026 | Serge Saxonov | CEO | Sale | 18,545 | $63.02 | $1.2M | Form 4 |
| Aug 24, 2026 | Adam Taich | CFO | Sale | 17,166 | $63.02 | $1.1M | Form 4 |
| Aug 24, 2026 | Benjamin J. Hindson | Director | Sale | 13,818 | $63.02 | $871K | Form 4 |
| Aug 24, 2026 | Shehnaaz Suliman | Director | Sale | 561 | $62.73 | $35.2K | Form 4 |
| Aug 24, 2026 | Shehnaaz Suliman | Director | Sale | 1,646 | $63.97 | $105K | Form 4 |
| Aug 14, 2026 | Sarah A. Teichmann | Director | Sale | 2,273 | $57.15 | $130K | Form 4 |
| Aug 13, 2026 | Sarah A. Teichmann | Director | Sale | 5,278 | $57.29 | $302K | Form 4 |
| Aug 11, 2026 | John R Stuelpnagel | Director | Sale | 3,000 | $58.73 | $176K | Form 4 |
| Aug 11, 2026 | John R Stuelpnagel | Director | Sale | 17,000 | $57.58 | $979K | Form 4 |
| Jun 22, 2026 | Serge Saxonov | CEO | Sale | 8,527 | $33.29 | $284K | Form 4 |
| Jun 22, 2026 | Serge Saxonov | CEO | Sale | 1,661 | $36.16 | $60.1K | Form 4 |
| Jun 22, 2026 | Serge Saxonov | CEO | Sale | 9,821 | $35.32 | $347K | Form 4 |
| Jun 22, 2026 | Serge Saxonov | CEO | Sale | 9,991 | $34.28 | $342K | Form 4 |
| Jun 16, 2026 | Shehnaaz Suliman | Director | Sale | 5,359 | $32.59 | $175K | Form 4 |
| Jun 16, 2026 | Shehnaaz Suliman | Director | Sale | 364 | $33.27 | $12.1K | Form 4 |
| May 26, 2026 | Serge Saxonov | CEO | Sale | 10,718 | $24.71 | $265K | Form 4 |
| May 22, 2026 | Serge Saxonov | CEO | Sale | 18,175 | $24.44 | $444K | Form 4 |
| May 22, 2026 | Benjamin J. Hindson | Director | Sale | 11,595 | $24.44 | $283K | Form 4 |
| May 22, 2026 | Adam Taich | CFO | Sale | 15,098 | $24.44 | $369K | Form 4 |
| Apr 14, 2026 | Serge Saxonov | CEO | Sale | 5,000 | $24.56 | $123K | Form 4 |
| Mar 24, 2026 | Serge Saxonov | CEO | Sale | 5,000 | $19.52 | $97.6K | Form 4 |
| Mar 23, 2026 | Serge Saxonov | CEO | Sale | 10,000 | $19.13 | $191K | Form 4 |
| Mar 2, 2026 | Serge Saxonov | CEO | Sale | 14,292 | $22.67 | $324K | Form 4 |
| Mar 2, 2026 | Serge Saxonov | CEO | Sale | 1,860 | $23.18 | $43.1K | Form 4 |
| Feb 25, 2026 | Sarah A. Teichmann | Director | Sale | 7,579 | $19.41 | $147K | Form 4 |
| Feb 23, 2026 | Serge Saxonov | CEO | Sale | 9,632 | $18.58 | $179K | Form 4 |
| Feb 23, 2026 | Adam Taich | CFO | Sale | 8,968 | $18.58 | $167K | Form 4 |
| Feb 23, 2026 | Benjamin J. Hindson | Director | Sale | 7,826 | $18.58 | $145K | Form 4 |
| Nov 24, 2025 | Adam Taich | CFO | Sale | 11,888 | $19.00 | $226K | Form 4 |
| Nov 24, 2025 | Benjamin J. Hindson | Director | Sale | 8,283 | $19.00 | $157K | Form 4 |
| Nov 24, 2025 | Serge Saxonov | CEO | Sale | 13,261 | $19.00 | $252K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Serge Saxonov | Chief Executive Officer, Director | – | $8.8M | Nov 10, 2026 |
| Adam Taich | Chief Financial Officer | – | $4.8M | Sep 9, 2026 |
| John R Stuelpnagel | Director | – | $2.4M | Sep 3, 2026 |
| Benjamin J. Hindson | See Remarks, Director | – | $1.5M | Aug 24, 2026 |
| Shehnaaz Suliman | Director | – | $792K | Sep 22, 2026 |
| Sarah A. Teichmann | Director | – | $579K | Aug 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TXG short interest
12.47M TXG shares are sold short. Over the last 12 reports the number of shares short went down 44%.
As of Oct 30, 2026, 12.47M TXG shares were sold short, down 2.0% from the report before. At the average daily volume of 3.02M shares, buying them all back would take about 4.1 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12.47M | – | -2% | 3.02M | 4.1 |
| Oct 15, 2026 | 12.73M | – | -17% | 4.80M | 2.6 |
| Sep 30, 2026 | 15.37M | – | -8% | 3.39M | 4.5 |
| Sep 15, 2026 | 16.69M | – | +3% | 2.35M | 7.1 |
| Aug 31, 2026 | 16.16M | – | +1% | 2.93M | 5.5 |
| Aug 14, 2026 | 15.93M | – | +2% | 3.48M | 4.6 |
| Jul 31, 2026 | 15.63M | – | -4% | 2.70M | 5.8 |
| Jul 15, 2026 | 16.25M | – | -1% | 3.04M | 5.3 |
| Jun 30, 2026 | 16.34M | – | -26% | 3.88M | 4.2 |
| Jun 15, 2026 | 22.10M | – | +34% | 3.26M | 6.8 |
| May 29, 2026 | 16.49M | – | -26% | 3.02M | 5.5 |
| May 15, 2026 | 22.15M | – | +36% | 2.79M | 7.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
10x Genomics company events
10x Genomics filed 7 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Nov 2, 2026LeadershipUpon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. appointed Ansuman Satpathy and Joseph Gilliam to the Board of Directors as Class III directors effective immediately, each with a term expiring at the Company's 2028 annual… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 8, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Feb 12, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
10x Genomics financials
Famous investors that hold TXG
8 of the 50 well-known investors we track reported holding TXG in their latest 13F filing. The largest position is Cathie Wood's, worth $567M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 6.27M | $567M | 3.3% | -37% |
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 747,087 | $67.5M | 0.2% | New |
| Lee Ainslie · Maverick Capital | Q3 2026 | 538,008 | $48.6M | 0.4% | New |
| Israel Englander · Millennium Management | Q3 2026 | 335,519 | $30.3M | 0.0% | +187% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 116,482 | $10.5M | 0.0% | +771% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 74,611 | $6.7M | 0.0% | -96% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 66,139 | $6M | 0.0% | -92% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 15,777 | $1.4M | 0.0% | -99% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named TXG in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 14.5% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 14.5% |
| Oct 7, 2026 | ARK Investment Management LLC | 13G/A | 5.2% |
| Oct 7, 2026 | ARK Investment Management LLC | 13G/A | 5.2% |
Questions about 10x Genomics, Inc. (TXG) stock
Who owns the most TXG stock?
The largest reported owner of 10x Genomics, Inc. (TXG) is FMR LLC (Fidelity). In total, 393 funds and institutions reported holding TXG at the end of Q2 2026. See the largest owners.
Are TXG insiders buying or selling?
In the last 12 months, TXG insiders reported no open-market purchases and 51 sales worth $18.8M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in TXG?
As of Oct 30, 2026, 12.47M TXG shares were sold short, down 2.0% from the report before. At the average daily volume of 3.02M shares, buying them all back would take about 4.1 trading days (days to cover). See the history.
Which famous investors hold TXG?
8 of the 50 well-known investors we track reported TXG in their latest 13F filing, including Cathie Wood, Andreas Halvorsen, Lee Ainslie. The largest position is worth $567M. See all holders.
Executive pay
10x Genomics's chief executive was paid a total of $6.3M for the year ended Dec 31, 2025, down 20% from $7.9M the year before. In the last 12 months, 10x Genomics's executives and directors bought no stock on the open market and sold $18.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.